Researchers at Baylor College of Medicine and collaborating institutions are challenging the traditional understanding of how cancer drugs called histone deacetylase (HDAC) inhibitors function. For decades, scientists believed that these drugs blocked HDAC enzymes, which drive cancer development by altering how genes are turned on and off.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗